FeesSafety
Pluang+

Eric Schmidt owns about half as much of AI startup Anthropic as its CEO, boosting his net worth if it goes public.

Market News
20 Oct 2026, 20:55 WIB
TechCrunch
View Source
Bullish
Eric Schmidt owns about half as much of AI startup Anthropic as its CEO, boosting his net worth if it goes public.

Eric Schmidt, former Google CEO, reportedly owns around 1% of AI startup Anthropic after investing millions in its 2021 Series A round. This stake is roughly half of what CEO Dario Amodei holds, who owns 2%. Anthropic is expected to go public by the end of 2026 with valuations possibly reaching $2 trillion, which could increase Schmidt's net worth by up to $20 billion. Schmidt has been an active tech investor since leaving Google, with multiple AI investments including Anthropic and others like Mistral and Reflection AI.

Eric Schmidt's reported 1% stake in AI startup Anthropic provides context for readers interested in tech investments. For readers following the Technology sector, here is Pluang's market snapshot as of Oct 21, 2026 00:31 WIB: out of 150 priced US tech stocks, 116 rose and 32 fell. Notable movers include Mondaycom Ltd (MNDY) up 8.61% at USD 101.46 with a typical hold time of 17 days, BlackBerry Limited (BB) up 7.48% at USD 8.77 with 69% buy order activity and a 51-day hold, and Asana Inc. (ASAN) up 7.00% at USD 10.86 with 100% buy order activity and a 35-day hold.

More News

Global beverage market to reach $2.78T by 2032, driven by nonalcoholic drinks and convenience trends.

Global beverage market to reach $2.78T by 2032, driven by nonalcoholic drinks and convenience trends.

The global beverage market is projected to grow from $2.03 trillion in 2026 to $2.78 trillion by 2032, at a CAGR of 5.35%. Growth is fueled by rising demand for nonalcoholic and functional beverages, convenience packaging, and premium products for sp...

Market News
Bullish
3 hours ago
Over 200 GLP-1 and incretin therapies in development are reshaping diabetes and obesity treatment landscapes.

Over 200 GLP-1 and incretin therapies in development are reshaping diabetes and obesity treatment landscapes.

DelveInsight's 2026 report reveals more than 200 GLP-1 receptor agonists and incretin-based therapies are in development by over 180 companies, targeting conditions like type 2 diabetes, obesity, and related metabolic disorders. Key players such as E...

Bullish
3 hours ago
Vylor reports mixed Q3 2026 results, confirms 2026 guidance, and launches $3B share buyback plus dividend.

Vylor reports mixed Q3 2026 results, confirms 2026 guidance, and launches $3B share buyback plus dividend.

Vylor, Inc. announced its Q3 2026 financial results showing a slight decline in net sales and increased losses compared to last year, mainly due to volume decreases from weather and market shifts. Despite this, the company saw strong demand for its h...

Company Fundamentals
Bullish
5 hours ago
Castle Biosciences to present company overview at Piper Sandler Healthcare Conference on Dec 2, 2026

Castle Biosciences to present company overview at Piper Sandler Healthcare Conference on Dec 2, 2026

Castle Biosciences, a diagnostics company specializing in tests for dermatologic and gastroenterological diseases, announced its executive management will present a company overview at the Piper Sandler 38th Annual Healthcare Conference on December 2...

Market News
Neutral
5 hours ago
Octave acquires Cerebre to enhance industrial AI with connected plant models for better facility management.

Octave acquires Cerebre to enhance industrial AI with connected plant models for better facility management.

Octave Intelligence plc has acquired Cerebre, a U.S.-based software firm that creates connected plant models by integrating engineering schematics and plant data. This acquisition aims to strengthen Octave's industrial AI capabilities, especially for...

Company Fundamentals
Bullish
5 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App